{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:28:27Z","timestamp":1790800107193,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T00:00:00Z","timestamp":1672185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004361","name":"Swiss Cancer League","doi-asserted-by":"publisher","award":["KFS-5442-08-2021"],"award-info":[{"award-number":["KFS-5442-08-2021"]}],"id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["310030_153211"],"award-info":[{"award-number":["310030_153211"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["316030_133860"],"award-info":[{"award-number":["316030_133860"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["200021_204602"],"award-info":[{"award-number":["200021_204602"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["316030_198526"],"award-info":[{"award-number":["316030_198526"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005243","name":"United Nations Educational, Scientific and Cultural Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008375","name":"Universit\u00e4t Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejmech.2022.115038","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T02:11:11Z","timestamp":1672193471000},"page":"115038","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor"],"prefix":"10.1016","volume":"248","author":[{"given":"Martina","family":"De Pascale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Bissegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Tarantelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Beaufils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Prescimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayget","family":"Mohamed Seid Hedad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Orbegozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Ragu\u017e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hebeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias P.","family":"Wymann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4688-8362","authenticated-orcid":false,"given":"Chiara","family":"Borsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.115038_bib1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nrm2335","article-title":"Lipid signalling in disease","volume":"9","author":"Wymann","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.115038_bib2","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2533\/chimia.2021.1037","article-title":"Targeting phosphoinositide 3-kinase - five decades of chemical space exploration","volume":"75","author":"Borsari","year":"2021","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2022.115038_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ceb.2005.02.011","article-title":"Phosphoinositide 3-kinase in disease: timing, location, and scaffolding","volume":"17","author":"Wymann","year":"2005","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.115038_bib4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115038_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110892","article-title":"Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks","volume":"441","author":"Magnuson","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2022.115038_bib6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.115038_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.ejmech.2022.115038_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.875372","article-title":"Recent advances in dual PI3K\/mTOR inhibitors for tumour treatment","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.115038_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/fnl.12.72","article-title":"A critical kinase cascade in neurological disorders: PI 3-K, Akt, and mTOR","volume":"7","author":"Chong","year":"2012","journal-title":"Future Neurol."},{"key":"10.1016\/j.ejmech.2022.115038_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1126\/science.273.5272.239","article-title":"Structure of the FKBP1 2-rapamycin complex interacting with the binding domain of human FRAP","volume":"273","author":"Choi","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.115038_bib11","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients","volume":"349","author":"Eisen","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.115038_bib12","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/aps.2015.68","article-title":"Toward rapamycin analog (rapalog)-based precision cancer therapy","volume":"36","author":"Meng","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2022.115038_bib13","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncol."},{"key":"10.1016\/j.ejmech.2022.115038_bib14","first-page":"43","article-title":"Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes","volume":"6","author":"Jerusalem","year":"2014","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejmech.2022.115038_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2174\/157488711793980147","article-title":"Recent clinical trials of mTOR-targeted cancer therapies","volume":"6","author":"Don","year":"2011","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.ejmech.2022.115038_bib16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/s41586-022-05213-y","article-title":"Brain-restricted mTOR inhibition with binary pharmacology","volume":"609","author":"Zhang","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib17","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/d41586-022-02892-5","article-title":"Two-drug trick to target the brain blocks toxicity in the body","volume":"609","author":"Wymann","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib18","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/cmdc.202100332","article-title":"Chemical and structural strategies to selectively target mTOR kinase","volume":"16","author":"Borsari","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.115038_bib19","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1158\/1535-7163.MCT-14-0711","article-title":"MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma","volume":"14","author":"Slotkin","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.115038_bib20","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1158\/1535-7163.MCT-14-1052","article-title":"CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization","volume":"14","author":"Mortensen","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.115038_bib21","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.bmcl.2013.01.019","article-title":"Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014","volume":"23","author":"Pike","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.115038_bib22","series-title":"Calithera Receives FDA Fast Track Designation for Sapanisertib for the Treatment of NRF2-Mutated Squamous Lung Cancer","year":"2022"},{"key":"10.1016\/j.ejmech.2022.115038_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13046-021-01968-w","article-title":"Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets","volume":"40","author":"Luo","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.115038_bib24","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1021\/ja043277y","article-title":"Characterization of the FKBP.rapamycin.FRB ternary complex","volume":"127","author":"Banaszynski","year":"2005","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.115038_bib25","doi-asserted-by":"crossref","first-page":"13595","DOI":"10.1021\/acs.jmedchem.0c00620","article-title":"4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a potent, orally available, and brain-penetrant mTOR inhibitor for the treatment of neurological disorders","volume":"63","author":"Borsari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib26","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1021\/acs.jmedchem.8b01262","article-title":"Discovery and preclinical characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1\/2 inhibitor for cancer and neurological disorders","volume":"61","author":"Rageot","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bmcl.2009.10.075","article-title":"Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K","volume":"20","author":"Verheijen","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.115038_bib28","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.jmedchem.9b01398","article-title":"Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders","volume":"63","author":"Bonazzi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib29","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.1021\/acs.jmedchem.9b00972","article-title":"A conformational restriction strategy for the identification of a highly selective pyrimido-pyrrolo-oxazine mTOR inhibitor","volume":"62","author":"Borsari","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1039\/D0MD00408A","article-title":"Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood-brain barrier permeability","volume":"12","author":"Borsari","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib31","article-title":"Stereospecific synthesis of substituted sulfamidates as privileged morpholine building blocks","author":"Stojiljkovic","year":"2022","journal-title":"Synthesis"},{"key":"10.1016\/j.ejmech.2022.115038_bib32","doi-asserted-by":"crossref","first-page":"7942","DOI":"10.1021\/jm901415x","article-title":"Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors","volume":"52","author":"Zask","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neuropharm.2018.08.002","article-title":"The novel, catalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy","volume":"140","author":"Brandt","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.115038_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107812","article-title":"Brain-penetrant PQR620 mTOR and PQR530 PI3K\/mTOR inhibitor reduce huntingtin levels in cell models of HD","volume":"162","author":"Singer","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.115038_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108297","article-title":"Novel brain permeant mTORC1\/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex","author":"Theilmann","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2022.115038_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.669518","article-title":"The anti-non-small cell lung cancer cell activity by a mTOR kinase inhibitor PQR620","volume":"11","author":"Zha","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2022.115038_bib37","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3390\/cancers11060775","article-title":"The novel TORC1\/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax","volume":"11","author":"Tarantelli","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.115038_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103578","article-title":"Morpholine as ubiquitous pharmacophore in medicinal chemistry: deep insight into the structure-activity relationship (SAR)","volume":"96","author":"Kumari","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12082-3","article-title":"Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular similarity search, chemocentric target profiling, and experimental evidence","volume":"7","author":"Venkanna","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.115038_bib40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/md20020120","article-title":"The tetrahydrofuran motif in polyketide marine drugs","volume":"20","author":"Fern\u00e1ndez-Pe\u00f1a","year":"2022","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2022.115038_bib41","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bmcl.2009.11.050","article-title":"Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)","volume":"20","author":"Kaplan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.115038_bib42","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1021\/acs.jmedchem.9b00348","article-title":"Discovery of 3-oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, and its application in novel inhibitors of the PI3K-AKT-mTOR pathway","volume":"62","author":"Hobbs","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14683","article-title":"Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention","volume":"8","author":"Bohnacker","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.115038_bib44","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib45","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/js980402t","article-title":"Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration","volume":"88","author":"Clark","year":"1999","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2022.115038_bib46","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1023\/A:1015040217741","article-title":"Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs","volume":"16","author":"Kelder","year":"1999","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2022.115038_bib47","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/acsmedchemlett.9b00333","article-title":"Preclinical development of PQR514, a highly potent PI3K inhibitor bearing a difluoromethyl-pyrimidine moiety","volume":"10","author":"Borsari","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.115038_bib48","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1016\/j.bmcl.2010.02.029","article-title":"Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha","volume":"20","author":"Richard","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.115038_bib49","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.1021\/acs.jmedchem.9b00525","article-title":"(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a potent, orally bioavailable, and brain-penetrable dual inhibitor of class I PI3K and mTOR kinase","volume":"62","author":"Rageot","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib50","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.bmcl.2010.07.104","article-title":"PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) inhibitor","volume":"20","author":"Venkatesan","year":"2010","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2022.115038_bib51","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jacs.1c13568","article-title":"Covalent proximity scanning of a distal cysteine to target PI3K\u03b1","volume":"144","author":"Borsari","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.115038_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib53","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1039\/b902330e","article-title":"Hydrogen-bond directionality at the donor H atom\u2014analysis of interaction energies and database statistics","volume":"11","author":"Wood","year":"2009","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejmech.2022.115038_bib54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-3-030-50621-6_9","article-title":"Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral\/parasitic infections","volume":"1274","author":"McPhail","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2022.115038_bib55","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting Plasmodium PI(4)K to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib56","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib57","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1021\/acs.jmedchem.8b00521","article-title":"Discovery of a potent, orally bioavailable PI4KIII\u03b2 inhibitor (UCB9608) able to significantly prolong allogeneic organ engraftment in vivo","volume":"61","author":"Reuberson","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.115038_bib58","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41586-018-0343-4","article-title":"Suppression of insulin feedback enhances the efficacy of PI3K inhibitors","volume":"560","author":"Hopkins","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.115038_bib59","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1158\/0008-5472.CAN-22-0602","article-title":"Challenges and emerging opportunities for targeting mTOR in cancer","volume":"82","author":"Wood","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.115038_bib60","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/ijms21031060","article-title":"Is there a role for dual PI3K\/mTOR inhibitors for patients affected with lymphoma?","volume":"21","author":"Tarantelli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.115038_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.12845","article-title":"Clinical activity of everolimus in relapsed\/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group","volume":"166","author":"Conconi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejmech.2022.115038_bib62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/1078-0432.CCR-17-1041","article-title":"PQR309 is a novel dual PI3K\/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy","volume":"24","author":"Tarantelli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.115038_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810157","article-title":"BH3 mimetics in hematologic malignancies","volume":"22","author":"Klener","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2022.115038_bib64","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.115038_bib65","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1021\/acs.oprd.9b00312","article-title":"Scalable, economical, and practical synthesis of 4-(difluoromethyl)pyridin-2-amine, a key intermediate for lipid kinase inhibitors","volume":"23","author":"Rageot","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.ejmech.2022.115038_bib66","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1107\/S0021889807029238","article-title":"SUPERFLIP\u2013 a computer program for the solution of crystal structures by charge flipping in arbitrary dimensions","volume":"40","author":"Palatinus","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2022.115038_bib67","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1107\/S0021889812016068","article-title":"EDMA: a computer program for topological analysis of discrete electron densities","volume":"45","author":"Palatinus","year":"2012","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2022.115038_bib68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: a complete structure solution, refinement and analysis program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2022.115038_bib69","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal structure refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr C Struct Chem"},{"key":"10.1016\/j.ejmech.2022.115038_bib70","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1107\/S1600576719014092","article-title":"Mercury 4.0: from visualization to analysis, design and prediction","volume":"53","author":"Macrae","year":"2020","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.ejmech.2022.115038_bib71","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2022.115038_bib72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat. Biotechnol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422009400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:23:23Z","timestamp":1778538203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422009400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":72,"alternative-id":["S0223523422009400"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115038","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.115038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115038"}}